Increased expression of S100A6 promotes cell proliferation in gastric cancer cells.

S100A6 is involved in regulating the progression of cancer. S100A6 can regulate the dynamics of cytoskeletal constituents, cell growth and differentiation by interacting with binding or target proteins. The present study investigated whether S100A6 affects cell proliferation in gastric cancer cells by stimulating several downstream factors. Firstly, the expression and localization of S100A6 were investigated using immunohistochemical staining, an immunoelectron microscopy and laser confocal scanning. A ChIP-Chip assay was performed to determine the downstream factors of S100A6 using promoter Chip analysis, including approximately the -800 to +200 regions around the transcription starting point. Polymerase chain reaction analysis was performed to confirm this. It was found that the intensity of S100A6 staining was markedly higher in the cytoplasm and nucleus, and its expression level correlated with that of the Ki67 protein. The overexpression of S100A6 also promoted cell proliferation in AGS and BGC823 cell lines, detected using a Cell Counting-Kit 8 assay. In cells overexpressing S100A6, the expression levels of interleukin (IL)-8, cyclin-dependent kinase (CDK)5, CDK4, minichromosome maintenance complex component 7 (MCM7) and B-cell lymphoma 2 (Bcl2) were noticeably increased. In conclusion, the increased expression of S100A6 promoted cell proliferation by regulating the expression levels of IL-8, CDK5, CDK4, MCM7 and Bcl2 in gastric cancer cells.

Introduction

S100A6 is a member of the S100 family, which is found localized to the cytoplasm and nucleus in a wide range of cell types (1,2). Several studies have shown that S100A6 may be involved in the regulation of cancer progression (3). At present, the deregulated expression of S100A6 during malignant transformation has been described in human pancreatic cancer (4), malignant thyroid neoplasms (5), colorectal carcinoma (6,7), malignant melanoma (8), breast cancer (9), prostate cancer (10,11) hepatocellular carcinoma (12) and renal cell carcinoma (13). Similar to other S100 proteins, S100A6 may promote cancer progression by specific involvement in cell survival and apoptotic pathways (14). In addition, S100A6 may interact with binding or target proteins, thereby regulating the dynamics of cytoskeletal constituents, cell growth and differentiation, and calcium homeostasis (1,14–17).

One possible mechanism underlying the effect of S100A6 in primary gastric cancer cells is in cell proliferation and DNA synthesis, which is supported by a previous study showing that the depletion of S100A6 in vascular endothelial cells increased the proportion of endothelial cells accumulating in the G2/M phase of the cell cycle (17). In addition, Joo et al (18) suggested that nuclear factor (NF)-κB can regulate the gene expression of S100A6 in the HepG2 human hepatoblastoma cell line. Therefore, S100A6 may be one of the downstream factors of NF-κB, which promotes cell-cycle progression. However, the precise mechanism of S100A6 as a key regulator of cell proliferation remains to be fully elucidated.

S100A6 is found localized to the nucleus in a wide range of cell types. ChIP-Chip (or ChIP-on-Chip), also known as genome-wide location analysis, is a technology used for isolating the genomic sites occupied by specific DNA binding proteins in living cells. This strategy can be used to annotate promoters in genomes by mapping the locations of the protein markers associated with these sites (19). The function of the eukaryotic promoter as an initiator for transcription is one of the most complex processes in molecular biology. These elements, including the TATA-box, GC-box, CAAT-box and the transcription start site, are known to function as binding sites for transcription factors and other proteins, which are involved in the initiation process. These promoter elements are present in various combinations separated by various distances in sequence.

In the present study, the expression and functional properties of S100A6, a major member of the S100 family, were investigated; primarily focusing on whether it affects cell proliferation in gastric cancer cells. The present study also investigated the downstream factors of S100A6.

Materials and methods

Patients and tissue specimens

In total, 196 patients with gastric cancer, including 132 males and 64 females (mean age, 57 years; age range, 26–80 years) were included in the present study and were diagnosed and surgically treated at Peking University Cancer Hospital (Beijing, China) between 1999 and 2007. Primary gastric carcinoma tissues and matched non-cancerous mucosal tissues were obtained from the patients and were fixed with 10% formaldehyde in PBS for immunohistochemistry. The investigations were performed following approval by the Ethics Committee of Peking University. General informed consent was obtained from each participant involved in the study.

Cell culture

The AGS and KATO 3 gastric cancer cell lines were obtained from American Type Culture Collection (Manassas, VA, USA). The BGC823 gastric cancer cell line was obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). The cell lines were routinely grown in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% (v/v) fetal calf serum (FCS; Gibco; Thermo Fisher Scientific, Inc.) and antibiotics at 37°C in a humidified 5% CO2 atmosphere.

Immunohistochemical analysis

Sections (4 µm) of the formalin-fixed, paraffin-embedded tissues were mounted on poly-L-lysine-coated slides, deparaffinized in xylene, rehydrated with alcohol and rinsed with distilled water. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 15 min at room temperature. Following heating the slides under pressure (120°C and 103 kPa/15 psi) in 10 mmol/l EDTA (pH 8.0) for 3 min, the sections were incubated overnight at 4°C with mouse anti-S100A6 monoclonal antibody (1:500; cat. no. H00006277-M16; Abnova, Taipai, Taiwan), or mouse Ki-67 monoclonal antibody (1:100; cat. no. MS-1794-S0; LabVision, Fremont, CA, USA). Primary antibodies were detected using a two-step EnVision system (Dako, Glostrup, Denmark). As a negative control, the primary antibody was replaced with nonimmune mouse serum (Dako) to confirm its specificity.

Evaluation of slides

Evaluation of the S100A6 staining was performed using previously described scoring criteria (20). The recorded information included the subcellular location of the S100A6 staining (nuclear and/or cytoplasmic), the intensity of staining (negative, weak, moderate and strong) and the percentage of cells demonstrating positive immunoreactivity.

The reactivity of Ki-67 was evaluated by counting the number of positive and negative tumor cell nuclei in at least four randomly selected fields in each section under a light microscope. The slides were visualized by two pathologists with no knowledge of the clinical data. Reproducibility of the scoring method between the two observers was >90%. In the remaining cases, if discrepancies were noted, the differences were settled through consensus following a review of the corresponding slides.

Laser confocal scanning

For double staining, mouse anti-human S100A6 antibody (1:500; Abnova) and rabbit anti-human Ki-67 antibody (1:100; cat. no. RM-9106-S0; LabVision) were used as the primary antibodies. The secondary antibodies used for double staining were fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse antibody and rhodamine (TRITC)-conjugated goat anti-rabbit antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Confocal images were captured using a Leica TCS SP5 confocal microscope (Leica Microsystems GmbH, Mannheim, Germany). The excitation wavelength for TRITC was 586 and for FITC was 488 nm. In addition, the nuclei of specimens were simultaneously stained with DAPI, with excitation at 358 nm.

Immunoelectron microscopy

The post-embedding immunogold method was used to detect the S100A6 proteins. The anti-S100A6 antibody, obtained from Abnova, was used at a dilution of 1:40. The gastric cancer tissues (1 mm3 in size) were immersed for 6 h in fresh glutaraldehyde fixative solution, following which the tissues were washed in 0.2 M sucrose and fixed in 1% osmium tetroxide for 4 h at 4°C. Subsequently, the tissues were dehydrated using a graded acetone series (−4°C), embedded in epoxy resin, and polymerized at 37°C for 24 h and 60°C for 48 h. Ultrathin sections (60 nm) were obtained on an ultramicrotome and collected on nickel grids. All sections were incubated in 10% H2O2, rinsed with phosphate-buffered saline enriched with 1% bovine serum albumin (Gibco; Thermo Fisher Scientific, Inc.) and 0.5% powdered skim milk three times (5 min each), and then incubated with the primary antibodies at 4°C overnight. Following incubation, the sections were washed three times in TBS (pH 7.6), following which the sections were incubated with goat anti-mouse IgG antibody conjugated to 10 nm gold particles (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) at a dilution of 1:100 in TBS (pH 7.6). The sections were rinsed three times (10 min each) in enriched TBS, rinsed three times (10 min each) in distilled water, and then stained with uranyl acetate and lead citrate. The sections were visualized and images were captured using a Zeiss 900 transmission electron microscope (Zeiss GmbH, Oberkochen, Germany).

Plasmids and S100A6 transfection

The cDNAs encoding human S100A6 were generated from human tissues using polymerase chain reaction (PCR) with the following forward and reverse primers containing BamHI and XhoI sites: Forward 5′-AAGGATCCTACCGCTCCAAGCCCAGC-3′ and reverse 5′-CTCGAGCGCCCTTGAGGGCTTCATTGTAGAT-3′. The PCR products were digested with BamHI and XhoI, and then directly subcloned into the BamHI and XhoI sites of pcDNA.3.1/myc-His C vectors (Invitrogen; Thermo Fisher Scientific, Inc.), which produce fusion proteins.

The AGS and BGC823 human gastric cancer cell lines were maintained in high-glucose Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10% FCS. At the time of transfection, the cells were 90% confluent. The cells in 6-well plates (8×105) were transfected with a total of 4.0 µg of plasmid DNAs using Lipofectamine™ 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The medium was replaced 6 h later. The cells were incubated at 37°C in a CO2 incubator for 48 h prior to assessment of transgene expression. G418 (300 ng/ml; Gibco; Thermo Fisher Scientific, Inc.) was used to screen and isolate the resistant colonies. The efficiency of stable transfection was confirmed using PCR and western blot analyses.

Reverse transcription-quantitative PCR (RT-qPCR) analysis

RT-qPCR was performed to confirm successful transfection of the cell lines with S100A6 and to determine the expression levels of interleukin (IL)-8, IL-2, IL-13, IL-6R, cyclin-dependent kinase (CDK) 4, CDK5, minichromosome maintenance complex component 7 (MCM7), B-cell lymphoma 2 (Bcl2) and MYC. Total RNA was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Total RNA (1 µg) was reverse transcribed using the GoScript™ Reverse Transcription System (Promega Corporation, Madison, WI, USA). qPCR was performed using the SYBR Green PCR Master Mix kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) with the following cycling conditions: 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec, 60°C for 10 sec and 72°C for 60 sec. Each sample was run thrice. The primer sequences were as follows: S100A6 forward, 5′-AAGCTGCAGGATGCTGAAAT-3′ and reverse, 5′-CCCTTGAGGGCTTCATTGTA-3′; IL-8 forward, 5′-ACTGAGAGTGATTGAGAGTGGAC-3′ and reverse, 5′-AACCCTCTGCACCCAGTTTTC-3′; IL-2 forward, 5′-AACTCCTGTCTTGCATTGCAC-3′ and reverse, 5′-GCTCCAGTTGTAGCTGTGTTT-3′; IL-13 forward, 5′-CCTCATGGCGCTTTTGTTGAC-3′ and reverse, 5′-TCTGGTTCTGGGTGATGTTGA-3′; IL-6R forward, 5′-CCCCTCAGCAATGTTGTTTGT-3′ and reverse, 5′-CTCCGGGACTGCTAACTGG-3′; CDK4 forward, 5′-ATGGCTACCTCTCGATATGAGC-3′ and reverse, 5′-CATTGGGGACTCTCACACTCT-3′; CDK5 forward, 5′-GGAAGGCACCTACGGAACTG-3′ and reverse, 5′-GGCACACCCTCATCATCGT-3′; MCM7 forward, 5′-CCTACCAGCCGATCCAGTCT-3′ and reverse, 5′-CCTCCTGAGCGGTTGGTTT-3′; Bcl2 forward, 5′-GGTGGGGTCATGTGTGTGG-3′ and reverse 5′-CGGTTCAGGTACTCAGTCATCC-3′; MYC forward, 5′-GGCTCCTGGCAAAAGGTCA-3′ and reverse, 5′-CTGCGTAGTTGTGCTGATGT-3′; and β-actin forward, 5′-AAATCTGGCACCACACCTTC-3′ and reverse, 5′-GGGGTGTTGAAGGTCTCAAA-3′. The expression of each gene was determined as the ratio of the mRNA expression of each target gene to that of β-actin, using the 2−ΔΔCq method (21).

Western blot analysis

Total proteins were extracted using TRIzol reagent, according to the manufacturer's protocol. Protein concentration was determined using a Bicinchoninic Acid Protein Assay kit (Thermo Fisher Scientific, Inc.). Samples were denatured in SDS sample loading buffer by heating at 100°C for 3 min and resolved by 12% SDS-PAGE, followed by transfer to polyvinylidene difluoride membranes. Blots were blocked with 5% nonfat milk in PBS for 30 min and then incubated with the mouse anti-S100A6 monoclonal antibody (1:2,000) and mouse anti-tubulin monoclonal antibody (1:5,000; cat. no. T5168; Sigma-Aldrich; Merck Millipore) for 2 h at room temperature. After washing, the membranes were incubated with the horseradish peroxidase-conjugated anti-mouse antibody (1:1,000; cat. no. sc-2005; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Protein-antibody complexes were visualized using the SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Inc.).

Cell proliferation assay

The BGC823, AGS, BGC823 cells transfected with pcDNA.3.1/myc-His C plasmid (BGC823/control), AGS cells transfected with pcDNA.3.1/myc-His C plasmid (AGS/control), BGC823 cells transfected with S100A6/pcDNA.3.1/myc-His C plasmid (BGC823/S100A6) and AGS cells transfected with S100A6/pcDNA.3.1/myc-His C plasmid (AGS/S100A6) were digested with trypsin-EDTA buffer (Gibco; Thermo Fisher Scientific, Inc.). A suspension of 2×103 cells/90 µl medium was added to each well of 96-well plates and allowed to grow; each concentration had three duplicate wells. The plates were incubated for 1, 2, 3, 4, 5 and 6 days following which 10 µl of Cell Counting Kit-8 (CCK8) solution (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was added to each well and the plates were incubated for another 2 h at 37°C. Subsequently, the absorbance was read at 450 nm using a Model 680 microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) (22).

ChIP-Chip assay. KATO3 cells (10,000,000) were prepared, crosslinked with 1% formaldehyde and lysed with lysate buffer. Sonication was used to break genomic DNA into small DNA fragments. Anti-S100A6 (Abnova) was added and used to immunoprecipitate DNA fragments corresponding to the promoter regions. IgG was used as a control. The DNA fragments bound by proteins were then isolated, and DNA was hybridized to the GLAS-H20K-Chip (Aviva Systems Biology, Corp., San Diego, CA, USA), with the transcription starting point approximately in the −800 to +200 regions. The microarray was then scanned, and two images corresponding to anti-S100A6 and IgG (control) were captured. Subsequently, the ratio between anti-S100A6 and IgG was calculated. The factors for which the ratio was >2 were selected. Gene Ontology (GO) analysis was then performed to clarify the gene function (http://geneontology.org).

Statistical analysis

Spearman's rank correlation was performed to analyze the correlation between the mRNA expression of S100A6 and Ki67. Two-way analysis of variance was performed to analyze the results of the CCK8 assay. P<0.05 was considered to indicate a statistically significant difference and all tests were two-tailed. The statistical analysis was performed using SPSS V16.0 software (SPSS, Inc., Chicago, IL, USA).

Results

Expression of S100A6 and its localization in gastric cancer tissues

A comparison between primary gastric carcinoma tissues and matched non-cancerous mucosal tissues revealed significant differences in the protein levels of S100A6 in these tissues. In the primary gastric carcinoma tissues, the intensity of S100A6 staining was markedly higher in the cytoplasm and nucleus of primary gastric carcinoma tissues, compared with the matched non-cancerous mucosa, which had either no or weak cytoplasmic staining. The S100A6 nuclear staining was significantly higher in the invading fronts with structural atypia, compared with the central portions with glandular structures (Fig. 1A and B). The ultrastructural images captured using an immunoelectron microscope showed that S100A6 was deposited within the cytoplasm and nucleus, whereas it was distributed in the nucleoplasmic and nucleolar structures in gastric cancer cells (Fig. 2A).

Figure 1.

Expression of S100A6 in primary gastric carcinoma, detected using immunohistochemical staining. (A) Image shows marked staining of S100A6 in the tumor (magnification, ×40). Higher magnification images to the right show S100A6 staining in the (top) central region of the tumor and (bottom) invasion in front of the primary tumor tissues (B) Representative images of the expression of S100A6 (cytoplasm+/nucleus+; cytoplasm+/nucleus−).

Figure 2.

Localization of S100A6 and the association between the expression of S100A6 and the Ki-67 antigen. (A) Ultrastructural localization of the expression of S100A6 in gastric cancer tissue, detected using immunoelectron microscopy: The cancer cells exhibit marked immunoreactivity, as indicated by gold labeling particles within the nucleus, including the nucleoplasm and nucleolus (indicated by the black arrow). Scale bar=0.5 µm. (B) S100A6-positive stained cancer cells (magnification, ×100). (C) Ki-67 was positive in the same sample (magnification, ×100), according to immunohistochemistry. (D) Immunofluorescence images captured by confocal laser scanning. Ki-67 (red; rhodamine-conjugated) was predominantly localized to the nucleus of cancer cells within the same positive areas of S100A6 (green; fluorescein isothiocyanate-conjugated). S100A6 subcellular localization included the cytoplasm (white arrows), whole nucleus and nucleolus (white arrowheads). Scale bar=10 µm. Nu, nucleus; nus, nucleolus.

Expression of S100A6 is associated with the Ki-67 labeling index

To investigate whether the expression of S100A6 was associated with in vivo cell proliferation, 108 samples underwent Ki-67 and S100A6 immunohistochemical staining, respectively. Statistical analysis revealed a positive correlation between high expression of S100A6 and a high Ki-67 labeling index (P=0.043; Fig. 2B and C). In total, 10 representative slides were selected for immunofluorescence staining and consecutive laser confocal scanning, which showed that the Ki-67 antigen was found localized to the nuclear region (Fig. 2D).

Effect of S100A6 transfection on cell proliferation

The correlation between S100A6 and cell proliferation was also investigated in vitro. Successful transfection of AGS and BGC823 cells with S100A6 was confirmed by western blotting (Fig. 3A and B). The present study examined whether S100A6 transfection promoted cell proliferation. The AGS, AGS/control, AGS/S100A6, BGC823, BGC823/control and BGC823/S100A6 cells were incubated for 1, 2, 3, 4, 5 and 6 days, and the growth rates were calculated using a CCK8 assay. The results suggested that the cell proliferation rate increased gradually and reached its highest level following 6 days of incubation. The proliferative abilities of the AGS/S100A6 and BGC823/S100A6 cells were markedly increased compared with those of the controls (Fig. 3C and D).

Figure 3.

S100A6 overexpression increases the proliferation in AGS and BGC823 cells. Ectopic expression of S100A6 in (A) AGS and (B) BGC823 cells at the protein level was confirmed by western blot analysis. The effect of S100A6 overexpression on the cell proliferation of (C) AGS cells and (D) BGC823 cells was evaluated by cell counting kit-8 assays.

S100A6 combines with the gene promoter region and promotes the expression of the downstream cancer-associated genes

Based on the above results, it was concluded that S100A6 was located at nucleolar structures and that it regulated cell proliferation. Subsequently, a ChIP-Chip assay was performed, with the promoter Chip including approximately −800 to +200 regions around the transcription starting point. The results showed the involvement of 1,328 genes, which regulate metabolic process, cell proliferation, cell cycle and cell apoptosis. GO category analysis suggested that 57 factors were associated with cell proliferation (Table I). In addition, the common sites of the promoter regions of the 1,328 involved genes were analyzed using the human and mouse promoter database (−100 to +1). The results showed that the promoter regions of the majority of genes had SP1 protein binding sites, for example the cartilage oligomeric matrix protein gene (Fig. 4A and B).

Table I.

Factors associated with cell proliferation detected using the ChIP-Chip assay.

Accession no.	Name	Ratio Ab/IgG	Description
NM_007037	ADAMTS8	9.76	ADAM metallopeptidase with thrombospondin type 1 motif, 8
NM_000584	IL-8	9.44	Interleukin-8
NM_000075	CDK4	9.25	Cyclin-dependent kinase 4
NM_005962	MXI1	7.66	MAX interactor 1
NM_145080	NSE1	5.45	Non-SMC element 1 homolog (S. cerevisiae)
NM_001352	DBP	4.67	Group-specific component (vitamin D binding protein)
NM_145307	PLEKHK1	4.62	Pleckstrin homology domain containing, family K member 1
NM_002188	IL-13	4.48	Interleukin-13
NM_002415	MIF	4.13	S100 calcium binding protein A9 (calgranulin B)
NM_002211	ITGB1	4.03	Integrin, β 1 (fibronectin receptor, β polypeptide, antigen CD29 includes MDF2, MSK12)
NM_001282	AP2B1	3.92	Adaptor-related protein complex 2, β 1 subunit
NM_006191	PA2G4	3.88	Proliferation-associated 2G4, 38 kDa
NM_014366	NS	3.82	Guanine nucleotide binding protein-like 3 (nucleolar)
NM_000565	IL-6R	3.55	Interleukin-6 receptor
NM_003711	PPAP2A	3.51	Phosphatidic acid phosphatase type 2A
NM_002457	MUC2	3.45	Mucin 2, oligomeric mucus/gel-forming
NM_001565	CXCL10	3.29	Chemokine (C-X-C motif) ligand 10
NM_005880	DNAJA2	3.25	DnaJ (Hsp40) homolog, subfamily A, member 2
NM_000369	TSHR	3.21	Thyroid stimulating hormone receptor
NM_000633	BCL2	3.18	B-cell CLL/lymphoma 2
NM_002825	PTN	3.15	Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1)
NM_153632	HOXA3	3.14	Homeobox A3
NM_182776	MCM7	3.11	MCM7 minichromosome maintenance deficient 7 (S. cerevisiae)
NM_002355	M6PR	3.10	Mannose-6-phosphate receptor (cation dependent)
NM_004935	CDK5	2.94	Cyclin-dependent kinase 5
NM_006510	RFP	2.93	Ret finger protein
NM_000595	LTA	2.90	Lymphotoxin α (TNF superfamily, member 1)
NM_000586	IL-2	2.86	Interleukin-2
NM_005438	FOSL1	2.86	FOS-like antigen 1
NM_005524	HES1	2.81	Hairy and enhancer of split 1, (Drosophila)
NM_198218	ING1	2.79	Inhibitor of growth family, member 1
NM_003254	TIMP1	2.72	TIMP metallopeptidase inhibitor 1
NM_005542	INSIG1	2.69	Insulin induced gene 1
NM_004236	TRIP15	2.62	COP9 constitutive photomorphogenic homolog subunit 2 (Arabidopsis)
NM_016041	F-LANa	2.54	Der1-like domain family, member 2
NM_001311	CRIP1	2.50	Cysteine-rich protein 1 (intestinal)
NM_020310	MNT	2.49	MAX binding protein
NM_003255	TIMP2	2.46	TIMP metallopeptidase inhibitor 2
NM_001233	CAV2	2.45	Caveolin 2
NM_173176	PTK2B	2.42	PTK2B protein tyrosine kinase 2 β
NM_000306	POU1F1	2.40	POU domain, class 1, transcription factor 1 (Pit1, growth hormone factor 1)
NM_006034	TP53I11	2.40	Tumor protein p53 inducible protein 11
NM_015902	DD5	2.39	E3 ubiquitin protein ligase, HECT domain containing, 1
NM_001981	EPS15	2.35	Epidermal growth factor receptor pathway substrate 15
NM_004429	EFNB1	2.35	Ephrin-B1
NM_015066	TRIM35	2.33	Tripartite motif-containing 35
NM_004356	CD81	2.31	CD81 molecule
NM_000508	FGA	2.26	Fibrinogen α chain
NM_005378	MYCN	2.24	v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)
NM_006763	BTG2	2.24	BTG family, member 2
NM_006763	BTG2	2.24	BTG family, member 2
NM_006292	TSG101	2.11	Tumor susceptibility gene 101
NM_006806	BTG3	2.09	BTG family, member 3
NM_033224	PURB	2.05	Purine-rich element binding protein B
NM_000194	HPRT1	2.02	Hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan syndrome)
NM_002467	MYC	2.02	Nucleolar protein 3 (apoptosis repressor with CARD domain)
NM_153719	NUP62	2.00	Nucleoporin 62 kDa

Figure 4.

Common sites identified in promoter region analysis. (A) COMP gene promoter; (B) protein binding site predictions. COMP, cartilage oligomeric matrix protein.

To confirm the effect of S100A6 on the expression of factors associated with the malignant cell phenotype, the present study compared the expression levels of IL-8, IL-2, IL-13, IL-6R, CDK4, CDK5, MCM7, Bcl2 and MYC prior to and following S100A6 transfection of the BGC823 and AGS cell lines. RT-qPCR analysis was performed, which revealed that, following S100A6 transfection in the AGS cell lines, the mRNA expression levels of IL-8, CDK5, CDK4, MCM7 and Bcl2 were increased (Fig. 5A-E, respectively).

Figure 5.

Alterations in the expression levels of downstream genes prior to and following S100A6 transfection. (A) IL8, (B) CDK4, (C) CDK5, (D) MCM7, and (E) Bcl-2. 1, AGS cells; 2, AGS/control cells; 3, AGS/S100A6 cells; IL-8, interleukin-8; CDK, cyclin-dependent kinase; MCM7, minichromosome maintenance complex component 7; Bcl2, B-cell lymphoma 2.

Discussion

S100A6 is a member of the S100 family of proteins, which are found localized to the cytoplasm and nucleus in a wide range of cell types. S100A6 is identified based on its cell cycle-dependent expression, as it is preferentially expressed in the G1 phase of the cell cycle following mitogenic stimuli. It has previously been suggested that the expression of S100A6 is associated with cell proliferation; it is expressed in several types of cancer phenotypes. S100A6 is implicated in the regulation of different cellular processes, including cell cycle progression, differentiation and apoptosis. However, the precise biological or cellular functions of S100A6 remain to be fully elucidated, and contradictory roles have been suggested (23).

Localization experiments suggested that S100A6 was present in the cytoplasm and nucleus, where it distributed to nucleoplasmic and nucleolar structures in the gastric cancer cells, and that immunostaining was significantly higher in the invading fronts. It is possible that the S100A6 protein performs multiple functions in the cytoplasm and nucleus of primary gastric cancer cells.

To further investigate the role of S100A6 in gastric cancer, the S100A6 gene was transfected into the AGS and BGC823 gastric cancer cell lines. The results of the CCK8 assay suggested that overexpression of S100A6 promoted cell proliferation. Thus, S100A6 affected cell proliferation in the AGS and BGC823 cell lines. In addition, a positive correlation between high expression levels of S100A6 and a high Ki-67 labeling index was found in vivo. These results confirmed that S100A6 was associated with the proliferation of gastric cancer cells.

Subsequently, the present study investigated how S100A6 affects cell proliferation. Examination of the expression of S100A6 in the gastric cancer cell lines revealed that the KATO3 cells had high levels of S100A6 in the cytoplasm and nucleus. Therefore, the KATO3 cells were selected to perform a ChIP-Chip assay. The ChIP-Chip assay was used to detect the gene promoter regions to which S100A6 may bind directly or indirectly. The ChIP-Chip results suggested that S100A6 may regulate the expression of 1,328 factors. Analyses of the GO categories included several genes, which are relevant to cell proliferation, cell migration and invasion. As evidence has suggested that S100A6 regulates the levels of certain genes involved in cell proliferation, including IL-8 (24), IL-2 (25), IL-13 (26), IL-6R (27), CDK4 (28), CDK5 (29), MCM7 (30), Bcl2 (29) and MYC (31), these genes were selectively assessed. To confirm and to evaluate their expression levels, mRNA quantification was performed. The overexpression of S100A6 caused a marked increase in the mRNA levels of CDK4, CDK5, IL-8, Bcl2 and MCM7. This overexpression is a consequence of the specific activation of the CDK4, CDK5, IL-8, Bcl2 and MCM7 gene promoters by S100A6, as demonstrated by the ChIP-Chip assay. Thus, S100A6 may affect the malignant cell phenotype by regulating the expression levels of CDK4, CDK5, IL-8, Bcl2 and MCM7.

The common sites of the promoter region in the 1,328 involved genes were predicted using the human and mouse promoter database (−100 to +1). The results showed that the promoter regions of the majority of genes had SP1 protein binding sites. The determination of how S100A6 binds to the gene promoters warrants further investigation. Previous reports have suggested that there is no DNA-binding domain in the S100A6 protein. S100A6 interacts with p53 in the presence of calcium ion affinity chromatography and co-immunoprecipitation (32). p53 can mediate the promoter attenuation of the cyclin B1 promoter, depending on the presence of functional Sp1 binding sites (33). Thus, further investigation is required to determine whether S100A6 binds to p53 and whether it is involved in the Sp1 binding sites.

In conclusion, the present study revealed that S100A6 was overexpressed in gastric cancer cells, in the cytoplasm and nucleus. Increased expression of S100A6 promoted cell proliferation in gastric cancer cells. A promoter ChIP-Chip assay was used to detect the gene promoter regions to which S100A6 may bind directly or indirectly, and 1,328 factors were found, including 57 factors associated with cell proliferation. The overexpression of S100A6 caused a marked increase in the mRNA expression levels of CDK4, CDK5, IL-8, Bcl2 and MCM7. In addition, S100A6 was associated with rRNA transcription. The results suggested that S100A6 may regulate cell proliferation by affecting the expression levels of the above-mentioned factors.